A Phase 3 interventional study of mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 15 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-18.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 25th largest by enrollment, is one of 21 that started in 2021, is one of 10 in phase 3, and was the 14th registered.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 19th largest by enrollment of the 22 interventional ones that give a count, is one of 8 that started in 2021, is one of 6 in phase 3, and was the 6th registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT) and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 and the serum antibody (Ab) responses obtained 28 days after the last dose of mRNA-1273.
7,993 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 234 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Transplant Recipients
Key Inclusion Criteria for Part A:
Key Exclusion Criteria for Part A:
Healthy Participants
Key Inclusion Criteria for Part A:
Key Exclusion Criteria for Part A:
Inclusion Criteria for Part B:
Exclusion Criteria for Part B:
Exclusion Criteria in Part A will apply except:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29. All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization. SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1. Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1.
Biological: mRNA-1273
Sterile liquid for injection
Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs)
An unsolicited AE was any AE reported by the participant that was not specified as a solicited adverse reaction (AR) or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to 28 days post-vaccination
Parts A and B: Number of Healthy Participants With Unsolicited AEs
An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Up to 28 days post-vaccination
Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs)
An MAAE was an AE that led to an unscheduled visit to an healthcare practitioner (HCP). This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
Parts A and B: Number of Healthy Participants With MAAEs
An MAAE was an AE that led to an unscheduled visit to an HCP. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 394)
Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs)
An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
Parts A and B: Number of Healthy Participants With SAEs
An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 394)
Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis
An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis
An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 394)
Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 394)
Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection
A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection
A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 394)
Parts A and B: Number of SOT Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 7 days post-vaccination
Parts A and B: Number of Healthy Participants With Solicited Local and Systemic ARs
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 7 days post-vaccination
Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay (PsVNA) specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 arbitrary units (AU)/milliliter (mL). The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
Time frame: Day 57 (for unvaccinated participants)
Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3
The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.
Time frame: 28 days after Dose 3
Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series
The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.
Time frame: 28 days after BD injection (BD-Day 29)
Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving the 2-Dose Regimen
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
Time frame: Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Part A: GMC of SARS-CoV-2-Specific nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
Time frame: 28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3
Part A: GMFR of nAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
Time frame: 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Part A: GMFR of nAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
Time frame: 28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3
Part A: Geometric Mean (GM) Value of Anti-SARS-CoV-2 S-specific Binding Antibody (bAb) for Unvaccinated Participants Receiving the 2-Dose Regimen
The GM level of VAC123 spike antibodies, as measured by MesoScale Discovery (MSD) electrochemiluminescence (ECL) multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
Time frame: Days 1, 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Part A: GM Value of Anti-SARS-CoV-2 S-specific bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen
The GM level of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
Time frame: 28 days after Dose 3, 6 months after Dose 3, and 1 year after Dose 3
Part A: Geometric Mean Fold-Rise (GMFR) of bAb for Unvaccinated Participants Receiving the 2-Dose Regimen Relative to Day 1
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
Time frame: 28 days after Dose 1, 28 days after Dose 2, 6 months after Dose 2, and 1 year after Dose 2
Part A: GMFR of bAb for Unvaccinated and Previously Vaccinated Participants Receiving the 3-Dose Regimen Relative to Day 1
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
Time frame: 28 days after Dose 3, 6 months after Dose 3, 1 year after Dose 3
Part A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection
Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR) central or local test or serology test as binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Part A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection
Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR1) central or local test or serology test as bAb level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Part A: Number of SOT Participants With the Occurrence of COVID-19
COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38 degree celsius \[°C\]/≥ 100.4 degree fahrenheit \[°F\]), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Part A: Number of Healthy Participants With the Occurrence of COVID-19
COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38°C/≥ 100.4°F), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Part A: Number of SOT Participants With the Occurrence of Severe COVID-19
Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Part A: Number of Healthy Participants With the Occurrence of Severe COVID-19
Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: 14 days after second and third injection
Parts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy
A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
Time frame: Throughout the study period (up to Day 450)
A total of 214 solid organ transplant (SOT) participants (137 SOT kidney and 77 SOT liver participants) and 20 healthy participants were enrolled for the study.
| Milestone | Part A (Primary Series): Cohort A1 - SOT Participants | Part A (Primary Series): Cohort A2 - SOT Participants | Part A (Primary Series): Cohort A3 - SOT Participants | Part A (Primary Series): Cohort A5 - Healthy Participants | Part B (Booster Dose): Cohort B2 - SOT Participants | Part B (Booster Dose): Cohort B3 - SOT Participants | Part B (Booster Dose): Cohort B4 - SOT Participants | Part B (Booster Dose): Cohort B5 - Healthy Participants |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 58 | 71 | 20 | 0 | 0 | 0 | 0 |
| Received first study injection | 3 | 58 | 0 | 20 | 0 | 0 | 0 | 0 |
| Received second study injection | 3 | 58 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received third study injection | 0 | 57 | 71 | 0 | 0 | 0 | 0 | 0 |
| Completed | 2 | 57 | 71 | 17 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Part A (Primary Series): Cohort A1 - SOT Participants | Part A (Primary Series): Cohort A2 - SOT Participants | Part A (Primary Series): Cohort A3 - SOT Participants | Part A (Primary Series): Cohort A5 - Healthy Participants | Part B (Booster Dose): Cohort B2 - SOT Participants | Part B (Booster Dose): Cohort B3 - SOT Participants | Part B (Booster Dose): Cohort B4 - SOT Participants | Part B (Booster Dose): Cohort B5 - Healthy Participants |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 33 | 44 | 82 | 10 |
| Received booster injection | 0 | 0 | 0 | 0 | 33 | 44 | 81 | 10 |
| Completed | 0 | 0 | 0 | 0 | 29 | 34 | 78 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 4 | 10 | 4 | 3 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 | 5 | 1 | 2 |
An unsolicited AE was any AE reported by the participant that was not specified as a solicited adverse reaction (AR) or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With Unsolicited Adverse Events (AEs) | 48 | 41 | 89 |
An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (that is, for the 7 days after each dose of vaccine). A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With Unsolicited AEs | 12 |
An MAAE was an AE that led to an unscheduled visit to an healthcare practitioner (HCP). This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With Medically-Attended Adverse Events (MAAEs) | 86 | 56 | 142 |
An MAAE was an AE that led to an unscheduled visit to an HCP. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory test results follow-up, COVID-19) and visits to HCPs external to the study site (for example, urgent care, primary care physician). MAAEs were also required by protocol for routine surveillance of participants with symptoms for COVID-19 infection (fever, shortness of breath, cough, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea). All confirmed symptomatic COVID-19 cases were recorded as MAAEs. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With MAAEs | 14 |
An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With Serious Adverse Events (SAEs) | 29 | 19 | 48 |
An AE (including an AR) was considered an SAE if, in the view of either the investigator or Sponsor, it results in any of the following outcomes: death, was life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital anomaly or birth defect, or medically important event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With SAEs | 1 |
An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With Adverse Event of Special Interests (AESIs), Including Myocarditis/Pericarditis | 15 | 13 | 28 |
An AESI was an AE (serious or non-serious) of scientific and medical concern specific to the Sponsor's product or program. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With AESIs, Including Myocarditis/Pericarditis | 1 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal) | 4 | 0 | 4 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With AEs Leading to Discontinuation From Dosing and/or Study Participation (Withdrawal) | 0 |
A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants With Adjudicated Biopsy-Proven Organ Rejection | 1 | 2 | 3 |
A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Parts A and B: Number of Healthy Participants With Biopsy-Proven Organ Rejection | 0 |
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Solicited Local ARs | 116 | 65 | 181 |
| Solicited Systemic ARs | 102 | 70 | 172 |
Solicited ARs, including local and systemic ARs were collected in the eDiary. Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. All solicited ARs (local and systemic) considered causally related to injection. ARs were graded 0-4 as reviewed and confirmed by Investigator; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered AEs. The Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Solicited Local ARs | 16 |
| Solicited Systemic ARs | 19 |
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay (PsVNA) specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values that were greater than the upper limit of quantification (ULOQ) were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 arbitrary units (AU)/milliliter (mL). The 95% confidence intervals (CIs) were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
| AU/mL | Part A: SOT Kidney (Unvaccinated Participants) | Part A: SOT Liver (Unvaccinated Participants) | Healthy Participants |
|---|---|---|---|
| Part A: Geometric Mean Concentration (GMC) of Serum SARS-CoV-2-Specific Neutralizing Antibody (nAb) After the Second Dose in Unvaccinated Participants | 54.2 (23.4 to 125.5) | 187.9 (67.6 to 522.6) | 1658.4 (951.1 to 2891.6) |
The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.
| AU/mL | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Part A: GMC of SARS-CoV-2-Specific nAb 28 Days After Dose 3 | 353.5 (171.2 to 729.7) | 1340.2 (617.4 to 2909.1) | 538.4 (307.2 to 943.7) |
The GMC of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were converted to the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation.
| AU/mL | Part B: SOT Kidney Participants | Part B: SOT Liver Participants |
|---|---|---|
| Part B: GMC of SARS-CoV-2-Specific nAb 28 Days After the BD in SOT Participants Who Received the Moderna Primary Series and Non-Moderna Primary Series | 430.7 (216.4 to 857.5) | 3946.0 (1944.5 to 8007.8) |
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
| AU/mL | Part A: SOT Kidney (Unvaccinated Participants) | Part A: SOT Liver (Unvaccinated Participants) | Healthy Participants |
|---|---|---|---|
| Day 1 | 13.9 (10.1 to 19.2) | 13.6 (8.0 to 23.2) | 11.2 (7.3 to 17.1) |
| 28 days after Dose 1 | 18.6 (11.1 to 31.2) | 28.4 (15.2 to 53.1) | 58.2 (31.4 to 107.8) |
| 28 days after Dose 2 | 54.2 (23.4 to 125.5) | 187.9 (67.6 to 522.6) | 1658.4 (951.1 to 2891.6) |
| 6 months after Dose 2 | 859.0 | 4134.0 | 948.5 (322.7 to 2787.6) |
| 1 year after Dose 2 | 412.0 | 7285.0 | 1439.3 (100.8 to 20561.0) |
The GMC of VAC62 antibodies, as measured by pseudovirus neutralization assay PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
| AU/mL | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| 28 days after Dose 3 | 353.5 (171.2 to 729.7) | 1340.2 (617.4 to 2909.1) | 538.4 (307.2 to 943.7) |
| 6 months after Dose 3 | 222.5 (72.7 to 681.4) | 867.2 (62.9 to 11960.3) | 292.1 (109.1 to 782.0) |
| 1 year after Dose 3 | 990.7 (198.6 to 4942.3) | 480.8 (NA to 4400000000000) | 899.7 (217.0 to 3729.4) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
| ratio | Part A: SOT Kidney (Unvaccinated Participants) | Part A: SOT Liver (Unvaccinated Participants) | Healthy Participants |
|---|---|---|---|
| 28 days after Dose 1 | 1.3 (0.8 to 2.1) | 2.1 (0.9 to 5.0) | 5.2 (2.7 to 9.9) |
| 28 days after Dose 2 | 3.7 (1.7 to 8.2) | 13.8 (3.7 to 51.9) | 148.4 (84.3 to 261.2) |
| 6 months after Dose 2 | 171.8 | 826.8 | 96.4 (36.8 to 252.8) |
| 1 year after Dose 2 | 82.4 | 1457.0 | 145.1 (11.8 to 1778.7) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC62 antibodies, as measured by PsVNA specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 10 and ULOQ was 111433 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMC value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
| ratio | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| 28 days after Dose 3 | 16.6 (6.6 to 41.7) | 56.8 (10.5 to 306.4) | 25.0 (11.2 to 55.9) |
| 6 months after Dose 3 | 16.2 (4.2 to 62.7) | 65.8 (3.0 to 1429.9) | 25.8 (7.7 to 86.7) |
| 1 year after Dose 3 | 990.7 (198.6 to 4942.3) | 480.8 (NA to 4400000000000) | 899.7 (217.0 to 3729.4) |
The GM level of VAC123 spike antibodies, as measured by MesoScale Discovery (MSD) electrochemiluminescence (ECL) multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
| AU/mL | Part A: SOT Kidney (Unvaccinated Participants) | Part A: SOT Liver (Unvaccinated Participants) | Healthy Participants |
|---|---|---|---|
| Day 1 | 68.3 (39.9 to 116.9) | 59.1 (33.6 to 104.0) | 53.6 (34.4 to 83.4) |
| 28 days after Dose 1 | 346.4 (127.7 to 939.6) | 1213.9 (269.5 to 5467.4) | 23668.2 (13462.8 to 41609.8) |
| 28 days after Dose 2 | 3190.1 (828.4 to 12284.7) | 20734.0 (3689.2 to 116527.2) | 272797.7 (188489.1 to 394816.2) |
| 6 months after Dose 2 | 84460.0 | 202997.0 | 97534.9 (47881.0 to 198681.0) |
| 1 year after Dose 2 | 44828.0 | 167863.0 | 161241.8 (19006.2 to 1367917.7) |
The GM level of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GM value, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
| AU/mL | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| 28 days after Dose 3 | 26674.0 (10865.9 to 65480.5) | 167141.1 (69651.7 to 401083.3) | 47260.9 (23657.2 to 94415.1) |
| 6 months after Dose 3 | 19289.6 (5878.6 to 63295.3) | 69076.5 (12838.6 to 371658.0) | 24895.7 (9274.4 to 66828.7) |
| 1 year after Dose 3 | 66847.7 (16994.7 to 262942.2) | 42266.8 (NA to 664919284614.9) | 62884.2 (18998.9 to 208139.7) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons. 95% CI cannot be calculated with an 'N' less than 2.
| ratio | Part A: SOT Kidney (Unvaccinated Participants) | Part A: SOT Liver (Unvaccinated Participants) | Healthy Participants |
|---|---|---|---|
| 28 days after Dose 1 | 4.9 (1.8 to 13.4) | 20.5 (4.3 to 97.0) | 441.9 (244.5 to 798.5) |
| 28 days after Dose 2 | 45.4 (10.7 to 191.8) | 399.0 (64.0 to 2488.0) | 5092.9 (3032.6 to 8553.1) |
| 6 months after Dose 2 | 2448.1 | 5884.0 | 1710.0 (755.9 to 3868.5) |
| 1 year after Dose 2 | 1299.4 | 4865.6 | 2567.2 (47.8 to 137952.8) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. The GMFR of VAC123 spike antibodies, as measured by MSD ECL multiplex assay specific to the SARS-CoV-2 spike protein is reported. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values that were greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 69 and ULOQ was 14400000 AU/mL. The 95% CIs were calculated based on the t-distribution of the log-transformed values or the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation. Results in healthy participants were included as reference not for any comparisons.
| ratio | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| 28 days after Dose 3 | 275.5 (60.9 to 1246.2) | 1556.2 (219.1 to 11051.0) | 490.7 (151.8 to 1586.4) |
| 6 months after Dose 3 | 554.9 (161.0 to 1912.2) | 824.1 (124.9 to 5436.5) | 633.1 (251.7 to 1592.5) |
| 1 year after Dose 3 | 690.8 (71.7 to 6656.9) | 746.2 (NA to 6400000000000) | 701.5 (114.3 to 4305.5) |
Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR) central or local test or serology test as binding antibody (bAb) level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Primary Series): Cohort A1 (SOT Kidney Participants) | Part A (Primary Series): Cohort A1 (SOT Liver Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants) |
|---|---|---|---|---|
| Part A: Number of SOT Participants With Asymptomatic SARS-CoV-2 Infection | 0 | 1 | 8 | 4 |
Asymptomatic SARS-CoV-2 infection was identified by absence of COVID-19 symptoms and infections as detected by reverse transcriptase polymerase chain reaction (RT-PCR1) central or local test or serology test as bAb level against SARS-CoV-2 nucleocapsid protein negative (as measured by Roche Elecsys) at Day 1 that became positive (as measured by Roche Elecsys) post-baseline or positive RT-PCR (CLIA-certified central or local) laboratory post-baseline at scheduled or unscheduled/illness visits. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Part A: Number of Healthy Participants With Asymptomatic SARS-CoV-2 Infection | 4 |
COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38 degree celsius \[°C\]/≥ 100.4 degree fahrenheit \[°F\]), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Primary Series): Cohort A1 (SOT Kidney Participants) | Part A (Primary Series): Cohort A1 (SOT Liver Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants) |
|---|---|---|---|---|
| Part A: Number of SOT Participants With the Occurrence of COVID-19 | 0 | 0 | 12 | 7 |
COVID-19 case was identified as a positive post-baseline RT-PCR (CLIA-certified central or local) laboratory for SARS-CoV-2, together with at least 2 systemic symptoms: fever (≥ 38°C/≥ 100.4°F), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s), or at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Part A: Number of Healthy Participants With the Occurrence of COVID-19 | 2 |
Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Part A (Primary Series): Cohort A1 (SOT Kidney Participants) | Part A (Primary Series): Cohort A1 (SOT Liver Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Kidney Participants) | Part A (Primary Series): Cohort A2 and A3 (SOT Liver Participants) |
|---|---|---|---|---|
| Part A: Number of SOT Participants With the Occurrence of Severe COVID-19 | 0 | 0 | 1 | 2 |
Severe COVID-19 case was identified as a COVID-19 case (RT-PCR \[CLIA-certified central or local\] laboratory) for SARS-CoV-2, together with any of the following: respiratory rate ≥30 per minute, heart rate ≥125 beats per minute, oxygen saturation(SpO2) ≤93% on room air at sea level, or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) \<300 millimeters of mercury (mmHg); or respiratory failure or acute respiratory distress syndrome (ARDS), defined as needing high-flow oxygen, noninvasive or mechanical ventilation, or extracorporeal membrane oxygenation) or evidence of shock (systolic blood pressure \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; OR admission to an intensive care unit or death. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | Healthy Participants |
|---|---|
| Part A: Number of Healthy Participants With the Occurrence of Severe COVID-19 | 0 |
A summary of serious adverse events (SAEs) and all nonserious AEs ("Other") reported up to the end of the study (up to Day 419), regardless of causality, is located in the Reported "Adverse Events" section.
| Participants | SOT Kidney Participants | SOT Liver Participants | SOT Total |
|---|---|---|---|
| Parts A and B: Number of SOT Participants Who Changed Immunosuppressant Therapy | 52 | 37 | 89 |
Collected over All-cause mortality and serious adverse events were collected throughout the entire period of the study (from Day 1 up to the end of study [Day 450]). Unsolicited AEs were collected for 28 days after the vaccination.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOT Kidney Participants | 4/137 (2.9%) | 28/137 (20.4%) | 49/137 (35.8%) |
| SOT Liver Participants | 0/77 (0%) | 17/77 (22.1%) | 38/77 (49.4%) |
| SOT Total | 4/214 (1.9%) | 45/214 (21%) | 87/214 (40.7%) |
| Healthy Participants | 0/20 (0%) | 1/20 (5%) | 13/20 (65%) |
| Event | SOT Kidney Participants | SOT Liver Participants | SOT Total | Healthy Participants |
|---|---|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 9/137 | 2/77 | 11/214 | 0/20 |
| Diverticulitis meckel'sCongenital, familial and genetic disorders | 0/137 | 0/77 | 0/214 | 1/20 |
| Urinary tract infectionInfections and infestations | 4/137 | 0/77 | 4/214 | 0/20 |
| Liver transplant rejectionImmune system disorders | 0/137 | 2/77 | 2/214 | 0/20 |
| Transplant rejectionImmune system disorders | 0/137 | 2/77 | 2/214 | 0/20 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/137 | 2/77 | 3/214 | 0/20 |
| SyncopeNervous system disorders | 0/137 | 2/77 | 2/214 | 0/20 |
| NauseaGastrointestinal disorders | 0/137 | 2/77 | 2/214 | 0/20 |
| VomitingGastrointestinal disorders | 1/137 | 2/77 | 3/214 | 0/20 |
| FallInjury, poisoning and procedural complications | 1/137 | 2/77 | 3/214 | 0/20 |
| Event | SOT Kidney Participants | SOT Liver Participants | SOT Total | Healthy Participants |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 2/137 | 1/77 | 3/214 | 3/20 |
| Urinary tract infectionInfections and infestations | 14/137 | 5/77 | 19/214 | 0/20 |
| Ear infectionInfections and infestations | 0/137 | 0/77 | 0/214 | 2/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/137 | 0/77 | 2/214 | 2/20 |
| Blood creatinine increasedInvestigations | 10/137 | 7/77 | 17/214 | 0/20 |
| Alanine aminotransferase increasedInvestigations | 2/137 | 6/77 | 8/214 | 0/20 |
| Aspartate aminotransferase increasedInvestigations | 1/137 | 5/77 | 6/214 | 0/20 |
| Abdominal painGastrointestinal disorders | 3/137 | 4/77 | 7/214 | 0/20 |
| NauseaGastrointestinal disorders | 2/137 | 4/77 | 6/214 | 1/20 |
| Blood urea increasedInvestigations | 2/137 | 4/77 | 6/214 | 0/20 |
Safety set included all participants who received at least 1 dose of study drug in this study.
| Age, Categorical(Participants) | SOT Kidney Participants | SOT Liver Participants | Healthy Participants | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 108 | 58 | 18 | 184 |
| >=65 years | 29 | 19 | 2 | 50 |
| Sex: Female, Male(Participants) | SOT Kidney Participants | SOT Liver Participants | Healthy Participants | Total |
|---|---|---|---|---|
| Female | 62 | 38 | 10 | 110 |
| Male | 75 | 39 | 10 | 124 |
| Ethnicity (NIH/OMB)(Participants) | SOT Kidney Participants | SOT Liver Participants | Healthy Participants | Total |
|---|---|---|---|---|
| Hispanic or Latino | 15 | 5 | 2 | 22 |
| Not Hispanic or Latino | 121 | 71 | 18 | 210 |
| Unknown or Not Reported | 1 | 1 | 0 | 2 |
| Race (NIH/OMB)(Participants) | SOT Kidney Participants | SOT Liver Participants | Healthy Participants | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 2 |
| Asian | 8 | 3 | 2 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 23 | 13 | 3 | 39 |
| White | 94 | 55 | 11 | 160 |
| More than one race | 1 | 2 | 0 | 3 |
| Unknown or Not Reported | 10 | 4 | 3 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in May 2023, 25 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 25 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 2019-nCoV Vaccine mRNA-1273